Edico Genome Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Edico Genome Inc.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In a recent interview Edico Genome's CEO describes how the company's technology can process genomics big data both rapidly and accurately.
Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.
- Research, Analytical Equipment & Supplies
- Synthesis Technologies, Production Processes
Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.